Cognition Therapeutics secures patent for new crystalline form of zervimesine
Cognition Therapeutics announced that the USPTO granted it U.S. Patent No. 12,759,979 covering a novel polymorphic crystalline form of its lead candidate, zervimesine. The patent naturally expires in 2045 and could qualify for a five‑year term extension if the drug receives FDA approval. The company plans to start manufacturing this form in the first quarter of 2027, pending a favorable outcome from an upcoming FDA meeting on trial endpoints.
Why it matters
The extended patent life and potential five‑year add‑on give the company longer exclusivity, which could improve the economics of a future Phase 3 trial and eventual commercialization, according to the company’s statements.
Key facts
- 1U.S. Patent No. 12,759,979 was issued for a crystalline form of zervimesine. stocktitan.net
- 2The patent’s natural expiration date is 2045. stocktitan.net
- 3If the drug is approved by the FDA, the patent could qualify for a five‑year extension. stocktitan.net
- 4Cognition plans to begin manufacturing the new form in Q1 2027 for a registrational trial. stocktitan.net
- 5A meeting with the FDA is scheduled for next week to finalize endpoint selection for the dementia with Lewy bodies program. stocktitan.net
- 6Anthony Caggiano, M.D., Ph.D., is the company’s chief medical officer. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.